<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="366">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01679847</url>
  </required_header>
  <id_info>
    <org_study_id>HSZL201001</org_study_id>
    <nct_id>NCT01679847</nct_id>
  </id_info>
  <brief_title>Blood Brain Barrier Penetration and Pharmacokinetics of the Elemene in Malignant Patients.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dalian Holley Kingkong Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dalian Holley Kingkong Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to elucidate the pharmacokinetics and the blood-brain barrier
      penetration of the elemene.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only</study_design>
  <primary_outcome>
    <measure>blood and cerebrospinal fluid concentration</measure>
    <time_frame>0，0.25，0.5，1，1.5，2，3，3.5，4，6，8，12 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Cancer</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and Cerebrospinal fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        malignant patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histopathological or cytopathology diagnosis of malignancy

          -  heart, liver and renal function is normal

          -  Expected survival time is more than 3 months

          -  Signed informed consent

        exclusion Criteria:

          -  non cancer patient

          -  accepted elemene administration in 1 month

          -  Expected survival time is less than 3 months

          -  no Signed informed consent

          -  heart, liver and renal function is abnormal
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>liang xiaohua, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ZHAN QIONG, MD</last_name>
    <phone>8621-52887162</phone>
    <email>zjoan2121@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huashan Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 7, 2012</lastchanged_date>
  <firstreceived_date>September 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elemene</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Blood-brain barrier</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
